<DOC>
	<DOCNO>NCT02368574</DOCNO>
	<brief_summary>Based value-based medicine , randomize clinical trial conduct compare role class II class III hysterectomy patient low risk early stag cervical cancer ( define tumor lesion less 2cm less 50 % stromal invasion ) .</brief_summary>
	<brief_title>Comparison Class II Class III Hysterectomy Early Stage Cervical Cancer Cervical Cancer</brief_title>
	<detailed_description>This 1:1 multi-center randomize trial class II hysterectomy plus node dissection experimental arm , class III hysterectomy plus pelvic node dissection control arm . Primary endpoint : ( 1 ) . 3-year diseases-free survival ( DFS ) rate ; ( 2 ) rate treatment-related toxicity ; ( 3 ) post-operation QoL ( include sexual function ) ( 4 ) treatment cost . Secondary endpoint areï¼š ( 1 ) rate pelvic and/or extra-pelvic relapse ; ( 2 ) overall survival ( OS ) rate ; ( 3 ) number retroperitoneal node dissection , ( 4 ) rate parametrial , margin pelvic/para-aortic node involvement .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1 . Stage IA2 small IB1 &lt; 2 cm 2 . Less 50 % stromal invasion base MRI OR 10mm stromal invasion base pathology measurement LEEP/cone specimen 3 . Squamous OR adenocarcinoma OR adenosquamous 4 . Grade 1 , 2 3 5 . Lymphvascular space invasion ( LVSI ) : presence absence 6 . Diagnosis confirm LEEP/cone/cervical biopsy 7 . Pelvic MRI patient involve cone/LEEP margin cervical biopsy 8 . Abdominopelvic CT scan patient negative LEEPcone margin 9 . No contraindication surgery 10 . No desire preserve fertility 11 . Informed consent 1 . Highrisk histology type ( clear cell , small cell etc ) 2 . Evidence lymph node metastasis preoperative imaging 3 . Stage 1A1 4 . Neoadjuvant chemotherapy 5 . Pregnancy 6 . Desire preserve fertility</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>